TGV Laboratories

TGV Laboratories was a New York-based pharmaceutical company focused on broad-spectrum anti-infective drug development, particularly candidates for resistant bacterial, fungal, and viral infections. Public materials from 2016 describe its lead programs as Mul-1867, an antimicrobial candidate advanced through preclinical and pilot clinical work and granted FDA orphan drug designation via subsidiary TGV-Inhalonix for cystic fibrosis-related resistant lung infections, and MV-4, a broad-spectrum antiviral discovery. Third-party company databases later characterized the company as archived or deadpooled, indicating it is no longer an active operating biopharma company. Available information suggests the business also referenced an Institute of Human Microbiology and operated through a subsidiary structure, but current corporate operations, financing, and commercial activity are not evident. Overall, TGV Laboratories appears to have been an early-stage infectious disease biotech/pharma developer rather than a commercial-stage company.